News|Articles|November 16, 2026

SNO 2026: Vorasidenib Updates Highlight Seizure Control in IDH-Mutant Glioma

Listen
0:00 / 0:00

Key Takeaways

  • Extended INDIGO follow-up in grade 2 IDH-mutant glioma supports durability of progression-free benefit and delayed next intervention, while not demonstrating overall survival benefit from the available previewed data.
  • Exploratory seizure and quality-of-life analyses suggest vorasidenib may delay worsening on FACT–Brain metrics in patients with seizures, but results are unadjusted, nonprespecified, and require confirmation.
SHOW MORE

Vorasidenib analyses featured at SNO 2026 examine longer-term outcomes and seizure burden in IDH-mutant glioma, underscoring the importance of sustained monitoring during oral therapy.

Vorasidenib (Voranigo; Servier) research featured at the 2026 Society for Neuro-Oncology (SNO) Annual Meeting extends the discussion of IDH-mutant glioma treatment beyond radiographic progression. The program included longer-term findings from the phase 3 INDIGO trial (NCT04164901) and an exploratory analysis examining seizure activity and quality of life. For pharmacists supporting patients through prolonged oral therapy, these outcomes bring everyday symptom burden into the assessment of treatment benefit.1,2

Held November 12–15, 2026, in Philadelphia, Pennsylvania, the meeting also featured retrospective studies of vorasidenib use outside the original trial population.1

Longer Follow-Up Builds on INDIGO

INDIGO enrolled 331 patients with residual or recurrent grade 2 IDH-mutant glioma who had received no anticancer treatment other than surgery. Patients were randomly assigned to vorasidenib 40 mg once daily or placebo. In the original publication, median progression-free survival was 27.7 months with vorasidenib versus 11.1 months with placebo, corresponding to a hazard ratio for progression or death of 0.39 (95% CI, 0.27–0.56; P < .001). Time to the next intervention was also significantly improved.3

The SNO program included an extended follow-up analysis, with a median follow-up duration of 41.6 months, examining outcomes across histological subtypes and other prognostic factors. Servier described sustained clinical benefit, although its preview did not report subgroup-specific effect estimates.1

The distinction matters when discussing expectations with patients: the original randomized results establish the treatment’s efficacy, whereas additional follow-up helps characterize how benefit persists over time. The preview alone does not establish an overall survival advantage.1,3

Seizure Burden Adds a Patient-Centered Perspective

An exploratory INDIGO presentation at SNO addressed seizure rates and quality of life. Earlier results addressing this question were reported at the 2026 American Society of Clinical Oncology Annual Meeting, providing context for the subsequent SNO presentation.2,4

In the exploratory analysis presented at ASCO 2026, investigators evaluated seizure activity and quality of life in patients with grade 2 IDH-mutant glioma. Among patients who experienced at least 1 seizure at baseline or during treatment, vorasidenib delayed the time to first worsening on the Functional Assessment of Cancer Therapy–Brain questionnaire compared with placebo (HR, 0.38; 95% CI, 0.15–1.00; P = .0435).4

These findings require careful interpretation. The analyses were exploratory, were not prespecified, and were not adjusted for multiple comparisons. They support further examination of symptom-related benefit rather than establishing vorasidenib as a replacement for antiseizure treatment. For pharmacy practice, they also highlight the value of asking about seizure frequency alongside medication adherence during follow-up.4

Real-World Findings Require Separate Interpretation

Servier also highlighted retrospective analyses involving 499 patients with grade 2 IDH-mutant glioma and 80 patients with grade 3 disease. The grade 2 analysis examined time to next intervention, while the smaller grade 3 cohort explored treatment experience beyond INDIGO’s population.1

These observational findings cannot establish the same causal conclusions as randomized evidence. Grade 3 use also falls outside the FDA-approved indication, which covers patients aged 12 and older with grade 2 astrocytoma or oligodendroglioma harboring a susceptible IDH1 or IDH2 mutation following surgery.1,5

Maintaining Safe Oral Therapy

As treatment continues, pharmacists can help ensure that laboratory monitoring keeps pace with prescription refills. Vorasidenib carries a hepatotoxicity warning. Liver laboratory tests should be assessed before treatment, every 2 weeks for the first 2 months, then monthly for the first 2 years, with additional testing as clinically indicated. Abnormal results can require treatment interruption, dose reduction, or discontinuation.5

Medication reconciliation is equally relevant. The prescribing information advises avoiding strong or moderate CYP1A2 inhibitors, moderate CYP1A2 inducers, and tobacco smoking. Vorasidenib can also reduce concentrations of certain CYP3A substrates and compromise hormonal contraceptive effectiveness. Reviewing concomitant medicines and reinforcing nonhormonal contraception counseling are practical components of ongoing pharmacy care.5

The SNO updates broaden the questions clinicians can ask about long-term vorasidenib treatment. Translating those findings into practice requires attention to the strength of each analysis while maintaining the safety measures that support continued therapy.1,4,5

REFERENCES
1. Servier highlights growing neuro-oncology portfolio with new data across pediatric and adult glioma at SNO 2026. News release. Servier Pharmaceuticals. November 6, 2026. Accessed November 16, 2026. https://servier.mediaroom.com/2026-11-06-Servier-Highlights-Growing-Neuro-Oncology-Portfolio-with-New-Data-Across-Pediatric-and-Adult-Glioma-at-SNO-2026
2. 2026 SNO Annual Meeting Abstracts. Neuro Oncol. 2026;28(suppl 4). Accessed November 16, 2026. https://academic.oup.com/neuro-oncology/issue/28/Supplement_4?
3. Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. 2023;389(7):589-601. doi:10.1056/NEJMoa2304194
4. Wick W, Mellinghoff IK, van den Bent MJ, et al. Impact of vorasidenib vs placebo on seizure rates and quality of life: exploratory analysis from the phase 3 INDIGO study. J Clin Oncol. 2026;44(suppl 16):2043. DOI: 10.1200/JCO.2026.44.16_suppl.2043
5. Voranigo. Prescribing information. Servier Pharmaceuticals LLC; June 2026. Accessed November 16, 2026.https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218784s004lbl.pdf

Related to this article